Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Betamethasone Camphor Cream (commonly known as Wuji Cream or Wuji Ointment) is a topical combination formulation developed by Zhejiang Yanan Pharmaceutical and other manufacturers for the treatment of various inflammatory and pruritic skin conditions. It is widely used to treat insect bite dermatitis, papular urticaria, eczema, contact dermatitis, neurodermatitis, and general skin itching. The formulation typically combines a potent corticosteroid (such as beclomethasone dipropionate or betamethasone) to suppress inflammatory and allergic responses, with counterirritants and local analgesics including camphor, menthol, methyl salicylate, borneol, and thymol. Together, these ingredients provide rapid cooling, anti-inflammatory, antipruritic, and local anesthetic effects to soothe irritated skin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound betamethasone camphor cream.